• Shortened clinical development program
• marketing approval and revenue stream targeted for 2021
• prostate cancer likely indication for initial marketing approval.
6 July 2017, Sydney: The Company’s NOX66 clinical development timetable and strategy has undergone significant development over the past 6 months. The change is regarded as material, obliging the Company to inform shareholders as well as the broader market.
For further information please download PDF attached:
Download this document
